Skip to main content
Top
Published in: Cancer and Metastasis Reviews 2/2015

01-06-2015

Five critical elements to ensure the precision medicine

Authors: Chengshui Chen, Mingyan He, Yichun Zhu, Lin Shi, Xiangdong Wang

Published in: Cancer and Metastasis Reviews | Issue 2/2015

Login to get access

Abstract

The precision medicine as a new emerging area and therapeutic strategy has occurred and was practiced in the individual and brought unexpected successes, and gained high attentions from professional and social aspects as a new path to improve the treatment and prognosis of patients. There will be a number of new components to appear or be discovered, of which clinical bioinformatics integrates clinical phenotypes and informatics with bioinformatics, computational science, mathematics, and systems biology. In addition to those tools, precision medicine calls more accurate and repeatable methodologies for the identification and validation of gene discovery. Precision medicine will bring more new therapeutic strategies, drug discovery and development, and gene-oriented treatment. There is an urgent need to identify and validate disease-specific, mechanism-based, or epigenetics-dependent biomarkers to monitor precision medicine, and develop “precision” regulations to guard the application of precision medicine.
Literature
4.
go back to reference Wu, X., Sun, X., Chen, C., Bai, C., & Wang, X. D. (2014). Dynamic gene expressions of peripheral blood mononuclear cells in patients with acute exacerbation of chronic obstructive pulmonary disease: a preliminary study. Critical Care, 18(6), 508.PubMedCentralPubMedCrossRef Wu, X., Sun, X., Chen, C., Bai, C., & Wang, X. D. (2014). Dynamic gene expressions of peripheral blood mononuclear cells in patients with acute exacerbation of chronic obstructive pulmonary disease: a preliminary study. Critical Care, 18(6), 508.PubMedCentralPubMedCrossRef
5.
go back to reference Chen, H., Wang, Y., Bai, C., & Wang, X. D. (2012). Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. Journal of Proteomics, 75(10), 2835–2843. doi:10.1016/j.jprot.2012.01.027.PubMedCrossRef Chen, H., Wang, Y., Bai, C., & Wang, X. D. (2012). Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. Journal of Proteomics, 75(10), 2835–2843. doi:10.​1016/​j.​jprot.​2012.​01.​027.PubMedCrossRef
9.
go back to reference Klauschen, F., Andreeff, M., Keilholz, U., Dietel, M., & Stenzinger, A. (2014). The combinatorial complexity of cancer precision medicine. Oncoscience, 1(7), 504–509.PubMedCentralPubMed Klauschen, F., Andreeff, M., Keilholz, U., Dietel, M., & Stenzinger, A. (2014). The combinatorial complexity of cancer precision medicine. Oncoscience, 1(7), 504–509.PubMedCentralPubMed
10.
go back to reference Dolsten, M., & Søgaard, M. (2012). Precision medicine: an approach to R&D for delivering superior medicines to patients. Clinical and Translational Medicine, 1(1), 7. doi:10.1186/2001-1326-1-7. Dolsten, M., & Søgaard, M. (2012). Precision medicine: an approach to R&D for delivering superior medicines to patients. Clinical and Translational Medicine, 1(1), 7. doi:10.​1186/​2001-1326-1-7.
11.
go back to reference Wilky, B. A., Rudek, M. A., Ahmed, S., Laheru, D. A., Cosgrove, D., Donehower, R. C., et al. (2015). A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. British Journal of Cancer, 112(1), 24–31. doi:10.1038/bjc.2014.515.PubMedCrossRef Wilky, B. A., Rudek, M. A., Ahmed, S., Laheru, D. A., Cosgrove, D., Donehower, R. C., et al. (2015). A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. British Journal of Cancer, 112(1), 24–31. doi:10.​1038/​bjc.​2014.​515.PubMedCrossRef
12.
13.
go back to reference Wang, X. D., Andersson, R., Soltesz, V., & Bengmark, S. (1992). Bacterial translocation after major hepatectomy in patients and rats. Archives of Surgery, 127, 1101–1106.PubMedCrossRef Wang, X. D., Andersson, R., Soltesz, V., & Bengmark, S. (1992). Bacterial translocation after major hepatectomy in patients and rats. Archives of Surgery, 127, 1101–1106.PubMedCrossRef
14.
go back to reference Wang, X. D., Andersson, R., Soltesz, V., Guo, W., & Bengmark, S. (1993). Water-soluble ethylhydroxyethyl cellulose prevents bacterial translocation induced by major liver resection in the rat. Annals of Surgery, 217, 155–167.PubMedCentralPubMedCrossRef Wang, X. D., Andersson, R., Soltesz, V., Guo, W., & Bengmark, S. (1993). Water-soluble ethylhydroxyethyl cellulose prevents bacterial translocation induced by major liver resection in the rat. Annals of Surgery, 217, 155–167.PubMedCentralPubMedCrossRef
15.
go back to reference Wan, X. D., & Ward, P. A. (2012). Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine. Journal of Translational Medicine, 10, 220. doi:10.1186/1479-5876-10-220.CrossRef Wan, X. D., & Ward, P. A. (2012). Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine. Journal of Translational Medicine, 10, 220. doi:10.​1186/​1479-5876-10-220.CrossRef
18.
go back to reference Lander, E. S. (2015). Cutting the Gordian helix—regulating genomic testing in the era of precision medicine. The New England Journal of Medicine. doi:10.1056/NEJMp1501964. Lander, E. S. (2015). Cutting the Gordian helix—regulating genomic testing in the era of precision medicine. The New England Journal of Medicine. doi:10.​1056/​NEJMp1501964.
Metadata
Title
Five critical elements to ensure the precision medicine
Authors
Chengshui Chen
Mingyan He
Yichun Zhu
Lin Shi
Xiangdong Wang
Publication date
01-06-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9555-3

Other articles of this Issue 2/2015

Cancer and Metastasis Reviews 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine